The 4DMedical Ltd (ASX:4DX) share price is soaring higher today as the company announced it completed its first commercial scan in Australia. In early trade, the 4DMedical share price shot up 6.1% to $2.24 but has since retreated to $2.19, up 3.79% at the time of writing.

What does 4DMedical do?

4DMedical is a Melbourne and Los Angeles-based software technology company commercialising its patented imaging platform, XV Technology.

This four-dimensional lung imaging technology utilises mathematic models and algorithms to convert X-ray scans into quantitative data. Physicians are then able to use this information to manage patients with respiratory and lung diseases.

The respiratory diagnostic sector represents a global market of more than US$31 billion per year.

What did 4DMedical announce?

In today’s release, 4DMedical advised that it has successfully completed the first XV lung ventilation analysis software (XV LVAS) scan to a patient. Conducted in Victoria, Australia, the accomplishment occurred ahead of schedule. The delivery of the first XV LVAS arrived in September, 2020, six months earlier than planned.

As a result, 4DMedical will now move to roll-out its infrastructure from early 2021. The XV LVAS is expected to be installed within hospitals and imaging centres across the country, offering greater accessibility for all patients.

All facilities with XV LVAS will be able to offer 4DMedical’s lung report for both inpatient and outpatient care. This in-turn will maximise the number of addressable patients for the company, effectively increasing revenue streams.

Management commentary

4DMedical CEO Andreas Fouras welcomed the progress, saying:

We’re pleased to hit yet another milestone ahead of schedule and see our end-to-end SaaS clinical solution perform flawlessly in a real-world setting.

COVID-19 has seen traditional spirometry assessments shut down and our technology also provides an excellent alternative for patients who need regular and more detailed lung health assessments.

While this might be our first ever Australian patient report, we expect to scale up quickly and begin to make a real difference to lung health in Australia.

How has the 4DMedical share price performed?

Since debuting on the ASX in August at a price of 73 cents, the 4DMedical share price has gone from strength to strength. For investors who picked up shares before the listing, they would be sitting on returns of more than 206%.

The company’s sharesreached an all-time high of $2.98 just 2 months ago, and are hovering 24% below.

More reading

• Why the 4DMedical (ASX: 4DX) share price is rocketing 8% today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 4DMedical (ASX:4DX) share price is climbing today on positive update appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/34nQO0s

The S&P/ASX 200 Index (ASX: XJO) looks set to end the week in a disappointing fashion. In late morning trade the benchmark index is down a sizeable 0.75% to 6,706.3 points.

Four shares that have fallen more than most today are listed below. Here’s why they are tumbling lower:

Mesoblast limited (ASX: MSB)

The Mesoblast share price has crashed 35% lower to $2.44. Investors have been heading to the exits after it revealed that its COVID-19 trial was unlikely to meet its 30-day mortality reduction endpoint. In addition to this, the US Data Safety Monitoring Board advised Mesoblast to essentially end the trial early and recruit no further patients. Management has suggested that changes in the treatment regimens for COVID-19 patients are to blame for the trial’s failure.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

The Paradigm share price has dropped 3% to $2.46. This is despite the biopharmaceutical company announcing that it has received feedback from the US Food and Drug Administration (FDA). This is in relation to its Zilosul product for the treatment of osteoarthritis. Investors may be disappointed that it will be over two years until the results of its Zilosul trial are available.

Qantas Airways Limited (ASX: QAN)

The Qantas share price is down 5% to $4.83. A number of travel shares have come under pressure today after the COVID-19 outbreak in New South Wales continued to grow. Western Australia has closed its border to the state and there are concerns that other states will soon follow suit. Border closures could possibly delay the recovery in the domestic travel market.

QBE Insurance Group Ltd (ASX: QBE)

The QBE share price has dropped 8.5% to $9.11. This follows the release of its guidance for FY 2020. According to the release, the insurance giant expects to report an adjusted net cash loss after tax of approximately $780 million. This includes a pre-tax impact of $470 million from COVID-19 costs. There are also additional claims from trade credit, lenders’ mortgage insurance, casualty classes and business interruption.

More reading

• Qantas (ASX:QAN) dobbed in to ACCC by rival
• The QBE (ASX:QBE) share price has plummeted 9% today. Here’s why
• Why the Mesoblast (ASX:MSB) share price crashed 45% lower today
• Why the Paradigm (ASX:PAR) share price is pushing higher today
• Qantas (ASX:QAN) didn’t rort JobKeeper, rules court

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why Mesoblast, Paradigm, Qantas, & QBE shares are tumbling lower appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3r4eHUu

Regional Express Holdings Ltd (ASX: REX) has dobbed in Qantas Airways Limited (ASX: QAN) for alleged anti-competitive practices.

Rex traditionally services regional and rural destinations but in March will start flying between Sydney, Melbourne and Brisbane in direct competition with Qantas, Jetstar and Virgin Australia.

In response, Qantas is planning to start some regional routes that it had not serviced before.

Rex on Friday accused its larger rival of “choosing to incur huge losses” on rural routes to “destroy incumbent regional operators”.

“The ACCC has been alerted to these actions,” stated Regional Express.

“Rex believes these actions are clearly anti-competitive and particularly unconscionable at a time when Qantas is receiving almost $1 billion of federal [government] assistance, while laying off thousands of workers under the pretext of reducing losses.”

All airlines are currently receiving government grants to keep services operating on economically unviable routes during the COVID-19 downturn.

Regional Express called for the federal government to stop providing Qantas this subsidy if it “persists with this opportunistic behaviour”.

The Motley Fool has contacted Qantas and the ACCC for comment.

Not enough demand for 2 airlines, says Rex

Rex cited Qantas’ announcement of a Sydney to Orange service as an example of deliberate loss-making.

“The Sydney–Orange market, which is barely big enough for one operator, [had] pre-COVID patronage of 65,000 annual passengers,” the company stated.

“Since its start of operations on 20 July 2020, at the height of the pandemic in Australia, it managed an average of only 10 passengers per flight, even for only 2 return services a week!”

The meagre annual patronage of other routes Qantas is starting on, according to Rex, are:

• 41,000 for Adelaide-Kangaroo Island
• 36,000 for Sydney-Merimbula
• 36,000 for Melbourne-Mt Gambier
• 5,500 for Adelaide-Mildura

Such incursions into its heartland, Rex warned, would have a “long-term negative impact” on regional areas.

“Unlike Rex, which has a long track record of providing a sustainable air service to regional and remote communities around Australia, Qantas is well known for quickly dropping a route once it no longer serves its strategic objectives,” Rex stated.

“If Qantas succeeds in driving Rex away from these routes, there is every possibility they will never have a regional service again when they are no longer relevant to Qantas.”

Regional Express’ share price has risen almost 50% since the start of October as its plans to fly between big cities ramped up. It’s currently down 6.37% in morning trade, to sell for $1.91.

Qantas shares were also down 4.9%, trading at $4.85 at the time of writing.

Corporate regulator Australian Securities and Investments Commission earlier this week reprimanded Rex for disclosing sensitive information to a journalist before telling the ASX.

The airline is now banned from releasing reduced-content prospectuses for raising capital on the exchange.

Rex has publicly disagreed with ASIC’s decision and reasoning.

More reading

• Why Mesoblast, Paradigm, Qantas, & QBE shares are tumbling lower
• Qantas (ASX:QAN) didn’t rort JobKeeper, rules court
• REX told off for blabbing to media rather than ASX
• Why Beacon Lighting, Flight Centre, REX, & Resolute Mining are shooting higher
• Why the Regional Express (ASX:REX) share price is soaring 10% higher today

Motley Fool contributor Tony Yoo owns shares of Qantas Airways Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Qantas (ASX:QAN) dobbed in to ACCC by rival appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3nIh2CF

Perseus Mining Limited (ASX: PRU) shares are on the rise this morning after the company announced it’s poured the first gold at its Yaouré Gold Mine five weeks ahead of plan. At the time of writing, the Perseus share price is up 1.54% to $1.32 in morning trade.

What did Perseus report?

This morning, the Perseus share price is pushing higher after the company advised it now expects to declare commercial production at its Yaouré Gold Mine in the Ivory Coast in the March 2021 quarter. Perseus also forecasts its first shipment of gold from the mine to occur in the same quarter.

Furthermore, the company revealed it believes it can increase its annual gold production to at least 500,000 ounces by the 2022 financial year (FY2022).

Commenting on the results, Perseus CEO Jeff Quartermaine said:

Pouring our first gold at Yaouré yesterday represented the achievement of a major milestone in the construction and commissioning of Perseus’ third gold mine. It also represented the delivery of another promise made to shareholders by Perseus’s management team, namely, to achieve its stretch target of first gold at Yaouré in December 2020…

We are now looking forward to achieving our next target of increasing our production to more than 500,000 ounces of gold per year at a cash margin of not less than US$400 per ounce in FY2022. We will also extend our capacity to consistently produce gold at these levels for many years to come by organically increasing our Ore Reserve inventory through successful near-mine exploration programs across our three mines.

Perseus share price and company snapshot

Perseus is a gold explorer and miner operating in Ghana and the Ivory Coast. Following on the successful development and commissioning of its Yaouré mine, the company will own and operate three gold mines, Edikan, Sissingué and Yaouré, across the two African nations .

Like most every share on the ASX, Perseus got hammered during the COVID driven market panic earlier in the year. The Perseus share price fell 44% from 21 February through to 13 March. Since the March low, Perseus shares are up 85%.

Year to date, the Perseus share price is up 13%. That compares to a 1% gain on the broader S&P/ASX 200 Index (ASX: XJO).

More reading

• ASX 200 drops on Friday
• Is it too late to buy the surging Bega (ASX:BGA) share price?
• ASX 200 rises more than 1% on Tuesday

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Perseus Mining (ASX:PRU) share price is gaining today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3p6HTrZ

The QBE Insurance Group Ltd (ASX: QBE) share price has dropped this morning after a company update on expected results for the 2020 financial year (FY20).

QBE will report its confirmed FY20 results to the market on 19 February 2021. At the time of writing, the QBE share price has dropped 9.35% to $9.02.

The $1.5 billion reason why QBE share price is sinking

In this morning’s update on QBE’s 2020 financial year expectations, the insurance giant advised it expected a full FY20 adjusted net cash loss after tax of approximately $780 million.

It listed pre-tax impacts of $470 million from COVID-19 costs. There included additional claims from trade credit, lenders’ mortgage insurance, casualty classes and business interruption.

QBE also reported a $130 million impact from elevated catastrophe costs. It expects total catastrophe costs to be around $680 million. That’s $130 million above its $550 million annual allowance. QBE said this figure is now well into the its catastrophe aggregate reinsurance program.

Atop this, the company expects to take a hit of $360 million from prior accident year claims development, up from $120 million as at 30 June.

Add in a $520 million impact from the non-cash writedowns of its North American goodwill and deferred tax assets, plus another $100 million of real estate and IT writedowns, and QBE now forecasts an expected statutory net loss after tax of around $1.5 billion.

Addressing the company’s reported expectations, QBE interim group CEO Richard Pryce said:

While I am very disappointed with the headline statutory loss, I am increasingly confident about the pricing cycle, particularly in the northern hemisphere, and the outlook for the underlying business. Premium rate momentum accelerated in North America and International during 3Q20 and the FY20 attritional claims ratio is expected to improve further from 45.5% reported in 1H20.

As we move into 2021, my focus remains on ensuring the group takes full advantage of currently favourable market conditions by locking in margin expansion while driving targeted growth in portfolios and regions offering the most profitable new business opportunities. Our balance sheet remains strong and able to fund expected growth.

QBE share price snapshot on 2020

QBE started the year strongly, with the share price gaining 17% by 21 February. It was then hit hard by the COVID-19 market panic, with shares falling 52% from that 2020 high through to the 23 March low.

Year-t0-date, the QBE share price is down 23%. By comparison the S&P/ASX 200 Index (ASX: XJO) is up 1%.

More reading

• Are ASX stocks in for an M&A frenzy in 2021?
• 5 things to watch on the ASX 200 on Friday
• ASX 200 rises on Thursday
• Leading broker just upgraded these ASX gold stocks to “buy”
• ASX stock of the day: Why are Netwealth (ASX:NWL) shares up 7%?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The QBE (ASX:QBE) share price has plummeted 9% today. Here’s why appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/387sMHW

The EMVision Medical Devices Ltd (ASX: EMV) share price has had a bumper week so far. Shares in the medical imaging company are up by 1.94% today, on the back of a week of gains. At the time of writing, the EMVision share price is up by 9.7% since the opening bell on Monday morning.

A week of good news for EMVision

EMVision’s gains this week come after the company announced on Monday that it had received a $1.28 million cash refund for the financial year ending 30 June 2020. The incentive was paid to EMVision in relation to its research and development (R&D) work.

This brings EMVision’s cash reserves to $13.1 million. Cash balance is of particular interest when looking at companies involved in R&D, where there are often gaps of time in between project developments.

On Thursday morning, EMVision announced the appointment of Professor Stuart Crozier as Chief Scientific Officer, noting that he is “globally recognised for his breakthroughs in Magnetic Resonance Imaging (MRI)”.

Professor Crozier will now lead R&D efforts of EMVision’s novel imaging products.

So what exactly does EMVision do?

Some Fools might recall us going into detail about what EMVision gets up to back in October. The company website states that EMVision “is developing a portable brain scanner for rapid, point of care, Stroke Diagnosis and Monitoring”.

If that sounds complicated, it’s probably because it is! Put simply, EMVision is working toward a solution that will support people suffering from a stroke, on-site. The company is currently developing a portable brain scanner that could save significant time diagnosing a stroke, therefore potentially lessening the impact of the stroke itself. 

According to a clinical trial result the company announced back in October, “It was observed that the EMVision device was able to classify stroke type (haemorrhagic or ischaemic) with an overall accuracy of between 93.3% and 96%.”

More on the EMVision share price

EMVision shares have had an impressive 12 months. Year-over-year, the share price has rocketed over 300%. During its December 2018 IPO, EMVision’s price was 25 cents a share. Lately, EMVision shares are trading in the $3 range, sitting at $3.16 at the time of writing.

With a market cap of around $213 million, EMVision certainly isn’t the biggest player on the field, but it seems to be garnering plenty of attention since joining the game. 

More reading

• The QBE (ASX:QBE) share price has plummeted 9% today. Here’s why
• Why Bapcor, Fortescue, Nufarm, & Saracen shares are pushing higher
• Genworth Mortgage (ASX:GMA) share price drops by 11%. Here’s why
• Why the BetMakers (ASX:BET) share price is surging 12% higher today
• Why the CleanSpace (ASX:CSX) share price is climbing today

The post Here’s why the EMVision (ASX:EMV) share price is up 9% this week appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2Kvp6I1

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a day in the red. The benchmark index is currently down 0.5% to 6,720.6 points.

Four shares that have not let that hold them back are listed below. Here’s why they are pushing higher:

Bapcor Ltd (ASX: BAP)

The Bapcor share price is up 3% to $7.76. This appears to have been driven by a broker note out of Morgan Stanley. In response to yesterday’s trading update, the broker has retained its overweight rating and lifted the price target on the company’s shares to $9.00.

Fortescue Metals Group Limited (ASX: FMG)

The Fortescue share price has pushed 2% higher to $22.83. Investors have been buying the mining giant’s shares after the price of iron ore rebounded overnight. According to CommSec, the spot iron ore price lifted US$1.65 or 1.1% to US$158.70 a tonne on concerns about tightening supply. This comes at a time when demand from the world’s largest steelmaker China remains robust.

Nufarm Ltd (ASX: NUF)

The Nufarm share price is up 3% to $4.26. This follows the release of its annual general meeting update this morning. The agricultural chemical company revealed that it recorded further strong revenue growth in October and November. Nufarm reported a 47% increase in revenue for the two months compared to the same period last year. Though, management acknowledges that these are relatively quiet months in the context of the full year of trading.

Saracen Mineral Holdings Limited (ASX: SAR)

The Saracen share price has risen 3% to $4.82. Investors have been buying Saracen and other gold miners on Friday after the gold price jumped higher overnight. The catalyst for this was meaningful progress in making an agreement for COVID-19 stimulus in the United States. The S&P/ASX All Ordinaries Gold index is up 1.2% at the time of writing.

More reading

• 5 things to watch on the ASX 200 on Friday
• 2 ASX growth shares to buy that keep delivering wins
• ASX 200 rises on Thursday
• Leading broker just upgraded these ASX gold stocks to “buy”
• Citigroup picks the best ASX retail stocks to own for 2021

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Bapcor. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why Bapcor, Fortescue, Nufarm, & Saracen shares are pushing higher appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/38clkvi

Genworth Mortgage Insurance Australia Ltd (ASX: GMA) shares have fallen by more than 11% in early morning trading, after the company announced a change to its reserving methodology will hit the bottom line by $110 million. As a result, the company says it is unlikely to report a profit or declare a dividend in FY20.

At the time of writing, the Genworth share price is trading at $2.24, down 25 cents.

Why the Genworth share price fell hard this morning

The Genworth share price is plunging lower today after the company advised an independent actuary was appointed to assess the potential impact of changes to delinquency behaviours and home loan repayment deferrals. The assessment formed part of the company’s annual earnings curve review.

In tandem with this review, the assessment also considered the appropriate timing of recognition and reserving for claims, given the changes to claims patterns arising from the COVID-19 borrower support packages.

Genworth says the introduction of repayment deferrals in response to the pandemic has interrupted the usual pattern of claim occurrence, notification and cure.

At the completion of the study, Genworth concluded that it is appropriate to “refine its reserving methodology”, and to hold re-delinquency claims reserves for all policies that have at any point experienced delinquency. This will apply to all policies currently cured and in force, and any new policies becoming delinquent from the fourth quarter of FY20 onwards. 

As a result of this update in reserving methodology, the company estimates that the pre-tax impact for the year ending 31 December 2020 (FY20) will be an increase in net claims incurred by $110 million.

Consequently, Genworth expects the fourth quarter FY20 net claims incurred to be in the range of $135 million to $150 million.

Given this announcement, the company says it is unlikely to report a statutory profit for FY20, and the board is unlikely to be in a position to declare a dividend for FY20.

About the Genworth share price

Genworth Mortgage is the provider of Lenders Mortgage Insurance (LMI) in Australia.

Back in November, the company announced steady results, reporting net profit after tax (NPAT) of $27.4 million for the third quarter, up from $26.5 million on the prior corresponding period.

The Genworth share price has lost 38% in 2020, including today’s losses. It is still a long way off from its 52-week high of $4.06. The company commands a market capitalisation of $1 billion.

More reading

• Why Bapcor, Fortescue, Nufarm, & Saracen shares are pushing higher
• Why the BetMakers (ASX:BET) share price is surging 12% higher today
• Why the CleanSpace (ASX:CSX) share price is climbing today
• Why the Mesoblast (ASX:MSB) share price crashed 45% lower today
• World’s 10 biggest companies are now worth 12% of Earth’s GDP

Motley Fool contributor Eddy Sunarto has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Genworth Mortgage (ASX:GMA) share price drops by 11%. Here’s why appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2KeKqBQ

BetMakers Technology Group Ltd (ASX: BET) shares are up by nearly 12% this morning after the company released a big market announcement. At the time of writing, the BetMakers share price has rocketed to 71.5 cents, just shy of its 52-week high of 76 cents. This comes on the back of a key development in a proposed acquisition for the company.

Why is the BetMakers share price on the move?

BetMakers announced on 1 December 2020 that it was set to acquire Sportech PLC‘s (LON: SPO) racing and digital assets. Today, BetMakers announced the Sportech board has terminated talks with another third party, Standard General.

The board has also urged shareholders to vote in favour of the resolution to approve the disposal of the assets to BetMakers.

That announcement has seen the BetMakers share price jump 11.72% higher in early trade as investors react to the news.

The board’s approval and recommendation has paved the way for the key acquisition of the assets.

Sportech’s  global tote business is being acquired by the Aussie betting technology group for total cash consideration of 30.9 million pounds sterling (A$55.1 million).

The acquired assets will include the North America-facing white label digital betting solutions business alongside other key assets.

In total, US$12.2 billion in stakes were processed for the year ended 31 December 2019 with clients in 37 countries.

How has the BetMakers share price performed this year?

The BetMakers share price has rocketed more than 400% higher in 2020 in what has been a bumper year for shareholders.

Shares in the Aussie wagering group are also currently yielding around 5% p.a. The group’s market capitalisation has also swelled to $388.0 million prior to the start of trade today.

Other ASX wagering shares are also climbing higher this year with the Pointsbet Holdings Ltd (ASX: PBH) share price up 167% in 2020 to $12.19.

Foolish takeaway

The BetMakers share price has rocketed higher in early trade to near its 52-week high. Today’s announcement by the Sportech board paves the way for the offshore acquisition towards the end of the year.

More reading

• Top ASX shares to buy in 2021
• The Pointsbet (ASX:PBH) share price just crashed 8%
• The Pointsbet (ASX:PBH) share price is up 170% in 2020. Here’s why
• Why BetMakers, Medical Development International, Qantas, & Zip are dropping lower
• Why the BetMakers (ASX:BET) share price is crashing 15% lower today

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Pointsbet Holdings Ltd. The Motley Fool Australia has recommended Pointsbet Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the BetMakers (ASX:BET) share price is surging 12% higher today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/38fzKL3

The CleanSpace Holdings Ltd (ASX: CSX) share price is up today after the company provided the market with a trading update to finish off the calendar year.

At the time of writing, the CleanSpace share price is up 4.55% at $6.90. 

A quick take on CleanSpace

CleanSpace designs, manufactures and sells workplace respiratory protection equipment (RPE) for healthcare and industrial end markets.

PAPRs are specialised respirators that come equipped with blowers, filters, respirator hood or face-pieces, and breathing tube assemblies. CleanSpace’s PAPRs operate in two markets, healthcare and industrial.

How is CleanSpace performing?

In today’s release, CleanSpace advised demand is continuing to outperform previous forecasts. Given the strong trading conditions, the company is now projecting revenue in the range of $39 million to $41 million. The upgraded guidance for the period ending 31 December, reflects an increase on the $34 million to $36 million originally announced on 12 November.

CleanSpace noted that its product and regional sales mix is tracking along similar to last month’s trading update. Healthcare and industrial is reported to be at a 77% and 23% split, respectively.

Group profit margin is predicted to be between 77% to 79%, with earnings before interest, tax, depreciation and amortisation (EBITDA) around the $17 million to $19 million mark.

Consumable sales are sitting at 47% of total sales, which is at the same level recorded last year.

In addition to the financial figures, the company highlighted that its new facility in St Leonards is now operational. Production capacity is running at 7,000 units pm which equates to $100 million per year for CleanSpace.

Cleanspace noted, however, that as the world approaches a vaccine roll-out for COVID-19, its current business environment remains uncertain.

In light of this, it did not provide a guidance for the second-half of the 2021 financial year.

CleanSpace share price summary

The CleanSpace share price is up more than 54% since its initial public offering (IPO) of $4.41 back in October. Its shares have levelled in the last month, where the broader All Ordinaries Index (ASX: XAO) has taken off.

CleanSpace has a market capitalisation of $508.3 million and a price-to-earnings (P/E) ratio of 60.5.

More reading

• Recent development sends the Antisense (ASX:ANP) share price soaring 45%
• With the Archer Materials (ASX:AXE) share price up 222% this year, what’s next?
• Why the BSA (ASX:BSA) share price has surged 7% higher today
• Why the Uniti (ASX:UWL) share price is on watch today
• Why Meteoric Resources (ASX:MEI) share price is soaring 6% higher

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has recommended CleanSpace Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the CleanSpace (ASX:CSX) share price is climbing today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3r4UXA1